Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y90 TARE with Gemcitabine and Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma
NCT02512692Phase 1Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jul 2015
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of yttrium-90 resin microspheres in intrahepatic cholangiocarcinoma (ICC), sponsored by Medical University of South Carolina. Primary endpoint: Feasibility of 90Y TARE in combination with gemcitabine and cisplatin at 2 years. Started Jul 2015; status: terminated.
02
Drugs
yttrium-90 resin microspheres
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02512692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512692.